Navigation Links
The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
Date:9/18/2007

WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade(R) (bortezomib) showed that the patients treated on the Velcade arm did better. These patients, who are not eligible for a stem cell transplant, experienced statistically significant benefit in terms of time-to-disease progression, complete response rate, progression-free survival and overall survival. Patients treated on the MP arm of the trial have the opportunity to switch over to the Velcade arm.

Detailed results from this trial will be presented at the American Society of Hematology annual meeting in early December.

"This is extremely encouraging news for myeloma patients," said Bart Kamen, M.D., Ph.D., the Society's chief medical officer. "However, while these results are very exciting, the Society reminds patients not to make any changes in their treatment regimen without speaking to their doctor first."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact:

Andrea Greif

914.821.8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
2. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
3. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
4. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
5. Major Gene Study Uncovers Secrets of Leukemia
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
10. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
11. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... PUNE, India , May 20, 2016 /PRNewswire/ ... Professional Survey Report 2016 to Medical Devices of ... professional and in-depth survey on the current state ... basic overview of the industry like definitions, classifications, ... gives information about manufacturing process like Raw Material ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... , May 19, 2016 According to a ... 2016-2017, G7 Countries, (U.S., Germany , ... Spain , and Japan )", published by ... 2021, at a CAGR of 13.9% from 2016 to 2021. ... Browse 14 market data Tables spread through 26 Pages and in-depth ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... , Roberta Jordan is a Certified Nurse Midwife who was born and ... and then went on to complete her masters degree from the University of ...
(Date:5/24/2016)... Fullerton, California (PRWEB) , ... ... ... Solutions, a nationwide provider of communication enabled solutions and managed services today ... cloud software for the enterprise contact center market. , Altura, one of ...
(Date:5/24/2016)... ... ... Brunswick, New Jersey: This year marks Children’s Specialized Hospital ’s 125th anniversary of ... the hospital has themed the milestone “Hats Off” and kicked off the yearlong celebration ... May 21, at Johnson Park in Piscataway, New Jersey. , “Hats Off” ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... Loma ... house the new adult hospital and expanded Children’s Hospital. Over 3,000 people looked on ... , Check out the event photo slidehsow. , During the program, Richard ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that improving life ... trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged – Insights ... the creative use of mobile digital devices can be an effective tool to help ...
Breaking Medicine News(10 mins):